User:Stand Out as a Thought Leader/sandbox
| Submission declined on 21 November 2023 by Theroadislong (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 16 November 2023 by Hey man im josh (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. This submission does not appear to be written in the formal tone expected of an encyclopedia article. Entries should be written from a neutral point of view, and should refer to a range of independent, reliable, published sources. Please rewrite your submission in a more encyclopedic format. Please make sure to avoid peacock terms that promote the subject. Declined by Hey man im josh 6 months ago. | |
| Submission declined on 8 November 2023 by Theroadislong (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by Theroadislong 6 months ago. | |
Comment: reads like a cCV? Theroadislong (talk) 11:26, 8 November 2023 (UTC)
Dr. Peter Kuhn | |
|---|---|
 | |
| Occupation | Cancer Physicist |
| Notable works | PiNK Test, Liquid Biopsy |
| Website | |
| kuhn.usc.edu | |
DR. PETER KUHN[edit]
Dr. Peter Kuhn is a scientist, educator and entrepreneur known for his contributions to personalized medicine and individualized patient care.[1] He is focused on the redesign of cancer care.[1]
HIGHLIGHTS[edit]
- Dr. Peter Kuhn is pioneering the development of the "PiNK Test," a blood-based screening method for breast cancer that could transform cancer detection and treatment monitoring.[2] This blood test, called liquid biopsy, may identify early-stage breast cancer and assess the likelihood of its recurrence.[3]
- Dr. Peter Kuhn participated in President Joe Biden's initiative, the Cancer Moonshot, aimed at reducing the national death rate from cancer by 50% in 25 years, alongside fellow USC cancer scientist John Carpten (February 2022).[4][5][2]
- Dr. Peter Kuhn is known for entrepreneurial ventures like founding Epic Sciences, Inc. in 2008 to develop cancer diagnostic products.[6] In 2012, Epic Sciences secured $13 million from venture capital investors to support the development of blood-based cancer tests detecting rare circulating tumor cells, aiding their market launch. [7] In 2018, Epic Sciences secured $52 million in funding to progress its range of cancer diagnostics and analytics.[8]
PASSION FOR CANCER CARE[edit]
Dr. Peter Kuhn, driven by personal experience with his mother's cancer diagnosis, transitioned from studying physics in Wuerzburg, Germany, to biomedical studies after an influential lecture in New York.[9]
His dedication to understanding cancer's spread via the bloodstream led to extensive research at Stanford University and the Scripps Research Institute before joining USC's Michelson Center.[9] At USC, Kuhn's focus on liquid biopsy aims to transform cancer detection, utilizing machine learning and a global data project.[9] In his roles as Dean’s Professor and leader of USC’s CSI-Cancer, Kuhn pioneers advancements like ATOM-HP and CancerBase for more tailored treatment decisions.[9]
REFERENCES[edit]
- ^ a b Staff, Daily Trojan (2015-01-27). "Dean's professor speaks on cancer treatment options". Daily Trojan. Retrieved 2023-11-21.
- ^ a b News, Mirage. "Could simple blood test detect cancer?". Mirage News. Retrieved 2023-11-16.
{{cite web}}:|last=has generic name (help) - ^ "Liquid Biopsy Detects Nano-Sized Signs of Breast Cancer in Early-Stage Patients". Diagnostics from Technology Networks. Retrieved 2023-11-16.
- ^ Herper, Matthew. "White House To Announce Big Push For Cancer Blood Tests". Forbes. Retrieved 2023-11-06.
- ^ News, Mirage. "2 University of Southern California scientists called to serve on Biden's renewed Cancer Moonshot initiative". Mirage News. Retrieved 2023-11-16.
{{cite web}}:|last=has generic name (help) - ^ "Cancer test maker Epic Sciences raises $52 million". Chicago Tribune. 2018-09-12. Retrieved 2023-11-21.
- ^ Twitter; Email; Facebook (2012-11-13). "Epic Sciences raises $13 million". San Diego Union-Tribune. Retrieved 2023-11-16.
{{cite web}}:|last1=has generic name (help) - ^ "Cancer test maker Epic Sciences raises $52 million". Chicago Tribune. 2018-09-12. Retrieved 2023-11-16.
- ^ a b c d "The power of fear drove cancer researcher Peter Kuhn toward his vocation". USC Today. 2018-11-23. Retrieved 2023-11-21.